Interstitial lung diseases

M Wijsenbeek, A Suzuki, TM Maher - The Lancet, 2022 - thelancet.com
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Immunology of human fibrosis

M Bhattacharya, P Ramachandran - Nature Immunology, 2023 - nature.com
Fibrosis, defined by the excess deposition of structural and matricellular proteins in the
extracellular space, underlies tissue dysfunction in multiple chronic diseases. Approved …

A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae

PM George, A Reed, SR Desai, A Devaraj… - Science translational …, 2022 - science.org
Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have
recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

[HTML][HTML] Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

J Åkesson, S Hojjati, S Hellberg, J Raffetseder… - Nature …, 2023 - nature.com
Sensitive and reliable protein biomarkers are needed to predict disease trajectory and
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a …

G Raghu, M Ghazipura, TR Fleming… - American journal of …, 2024 - atsjournals.org
Background: Idiopathic pulmonary fibrosis (IPF) carries significant mortality and
unpredictable progression, with limited therapeutic options. Designing trials with patient …

[HTML][HTML] De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

A Roy, L Shi, A Chang, X Dong, A Fernandez… - Nature …, 2023 - nature.com
Abstract The RGD (Arg-Gly-Asp)-binding integrins αvβ6 and αvβ8 are clinically validated
cancer and fibrosis targets of considerable therapeutic importance. Compounds that can …

Proteomic biomarkers of survival in idiopathic pulmonary fibrosis

JM Oldham, Y Huang, S Bose, SF Ma… - American Journal of …, 2024 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis (IPF) causes progressive lung scarring and high
mortality. Reliable and accurate prognostic biomarkers are urgently needed. Objectives: To …

[HTML][HTML] Recent advances of artificial intelligence applications in interstitial lung diseases

KP Exarchos, G Gkrepi, K Kostikas, A Gogali - Diagnostics, 2023 - mdpi.com
Interstitial lung diseases (ILDs) comprise a rather heterogeneous group of diseases varying
in pathophysiology, presentation, epidemiology, diagnosis, treatment and prognosis. Even …

CYFRA 21-1 predicts progression in idiopathic pulmonary fibrosis: a prospective longitudinal analysis of the PROFILE cohort

PL Molyneaux, WA Fahy, AJ Byrne… - American journal of …, 2022 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal condition
for which there are a lack of effective biomarkers to guide therapeutic decision making …

[HTML][HTML] Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression

P Ruan, JL Todd, H Zhao, Y Liu, R Vinisko… - Respiratory …, 2023 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of
extracellular matrix in the pulmonary interstitium and progressive functional decline. We …